Pharmacogenetic of Salbutamol in Pediatric Asthma Crisis

Pharmacogenetic of the Salbutamol Efficacy in Asthma Crisis for Children in Emergency Department

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02195258

Acronym

Pegase

Enrollment

Registered

2014-07-21

Start date

2010-11-30

Completion date

2013-06-30

Last updated

2014-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

this study is designed to identify the genetic factors which can be implicated in the salbutamol responsiveness for asthmatic children in pediatric emergency department

Detailed description

Patients from 6 to 16 years old consulting for an acute asthma exacerbation and receiving a treatment by salbutamol according to the usual care could be recruited.Saliva from patient were collected using Oragen®.DNA OG-500 kit or swabs.Based on literature review, four SNP were chosen:ADBR2 gene), ARG gene, and GSNOR gene.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

6 Years to 16 Years

Healthy volunteers

Inclusion criteria

* children * 6-16 years old * asthmatic patients * consulting for an exacerbation in a pediatric emergency department * parental informed consent

Exclusion criteria

* comorbidity * peak flow no available * pneumonia

Design outcomes

Primary

Measure	Time frame	Description
pre- and post-bronchodilator FEV1 value (BDR = 100 x [post-FEV1 - pre-FEV1]/pre-FEV1)	Day 0	comparison of acute response to salbutamol calculated as the percentage difference between the pre- and post-bronchodilator FEV1 value (BDR = 100 x \[post-FEV1 - pre-FEV1\]/pre-FEV1) between the different polymorphism

Secondary

Measure	Time frame
polymorphism on the response delay	Day 0

Countries

France

Outcome results